A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women
Latest Information Update: 09 May 2022
At a glance
- Drugs V 503 (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
- Indications Anal cancer; Cervical cancer; Condylomata acuminata; Human papillomavirus infections; Vulvovaginal cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms FUTURE 9
- Sponsors Merck & Co; Merck Sharp & Dohme
- 15 May 2018 Subgroup analysis results of participants from Asian countries (n = 1717) were published in the Journal of Infectious Diseases.
- 10 Oct 2017 Data from this trial were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) congress 2017, as reported in a Merck AG Media Release.
- 10 Oct 2017 Results published in the Merck AG Media Release